SINOVAC Biotech Ltd. ("SINOVAC") is a China-based leading biopharmaceutical company that focuses on the research, development, production, and commercialization of vaccines that protect against human infectious diseases.
More2026/05/30
BEIJING, China May 29, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it re
May 27, 2026 — SINOVAC has received approval from the National Medical Products Administration (NMPA) to launch clinical trials for its Influenza Vaccine (Split Virion), Inactivated (MDCK cell). The P
2026/05/27
BEIJING -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has extended the dead
2026/05/21
DHAKA, Bangladesh, May 13, 2026 — Sinovac Foundation, an affiliate of Sinovac Biotech Ltd. (SINOVAC), has donated 76,616 vials (383,080 doses) of the company’s Poliomyelitis Vaccine (Vero Cell), Inact
2026/05/13
SINOVAC has undertaken nearly 60 national and regional science and technology
R&D projects; received two State Scientific and Technology Progress Awards
and three national-level institutional technology awards; and published more than
140 SCI papers, many of which were published in top academic journals including
New England Journal of Medicine, The Lancet, Science and Nature, etc.
SINOVAC approved products include: COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac®, Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive®, Hepatitis A Vaccine (Human Diploid Cell) Inactivated - Healive®, Influenza Vaccine (Split Virion), Inactivated - Anflu®, 23-valent Pneumococcal Polysaccharide Vaccine, Varicella Vaccine(Live), Mumps Vaccine(Live), etc.